Immune checkpoint inhibitors (ICIs) have increased overall survival (OS) in metastatic melanoma in all clinical trials to date. However, pivotal trial populations were not representative of the real-world population in New Zealand. Real-world treatment effectiveness studies help evaluate the value of public pharmaceutical expenditure.

中文翻译：

---

接受免疫检查点抑制剂治疗的转移性黑色素瘤患者生存结局的新西兰全国回顾性队列研究

迄今为止，在所有临床试验中，免疫检查点抑制剂 (ICI) 均提高了转移性黑色素瘤的总生存期 (OS)。然而，关键试验人群并不能代表新西兰的现实世界人群。真实世界的治疗效果研究有助于评估公共医药支出的价值。